ARCHIVES

Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

SSO Education Group Lists “Major Unmet Needs, Problems”

November 25, 1983

Officals: “Separations” in Normal Range as Critics Claim Brain Drain in the Clinic

January 17, 2014

In Brief: Chance for Rauscher Pay Increase Bill Seems Diminishing, But Schmidt Remains Confident

April 30, 1976

ACS Prostate Cancer Recommendations Move Forward

August 7, 1992

What Peace Divided? Mideast Crisis Means NCI Will Be Lucky To Keep House Increase

August 31, 1990

FDA Approves Xeloda For Breast Cancer Treatment.

September 28, 2001